ReviewFrontiers in pharmacology2015
Importance of Apolipoprotein A-I in Multiple Sclerosis.
Review in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Association of vitamin B1/B6/B12 supplementation with sphingosine-1-phosphate signaling and its receptors in multiple sclerosis patients: relevance to LISPR1 and APOA1-AS.Bioscience reports · 2026Observational
- The Role of Lipid Alteration in Multiple Sclerosis.International journal of molecular sciences · 2026Review
- Plant-based flavonoids and their nanoparticles: Latest arsenal against Alzheimer's disease.Drug delivery and translational research · 2025Review
- Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights.International journal of molecular sciences · 2025Review
- The Cross-Talk Between the Peripheral and Brain Cholesterol Metabolisms.Current issues in molecular biology · 2025Review
- Protective Role of High-Density Lipoprotein in Multiple Sclerosis.Antioxidants (Basel, Switzerland) · 2024Review
- Nanocarrier drug delivery system: promising platform for targeted depression therapy.Frontiers in pharmacology · 2024Review
- Lipid Profile in Multiple Sclerosis: Functional Capacity and Therapeutic Potential of Its Regulation after Intervention with Epigallocatechin Gallate and Coconut Oil.Foods (Basel, Switzerland) · 2023Article
- Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.International journal of molecular sciences · 2021Article
- CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes.Scientific reports · 2021Article
- TemporalACS omega · 2020Article
- Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability.Journal of advanced research · 2020Article
- Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia.Heliyon · 2019Article
- Changes to the Human Serum Proteome in Response to High Intensity Interval Exercise: A Sequential Top-Down Proteomic Analysis.Frontiers in physiology · 2019Article
- Lipid-Binding Proteins in Brain Health and Disease.Frontiers in neurology · 2019Review
- Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL.Scientific reports · 2017Article
- HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Neutrophil-to-apolipoprotein A1 ratio as a novel biomarker for prognosis in anti-NMDAR encephalitis: a retrospective cohort analysis.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Jean-Martin Charcot has first described multiple sclerosis (MS) as a disease of the central nervous system (CNS) over a century ago. MS remains incurable today, and treatment options are limited to disease modifying drugs. Over the years, significant advances in understanding disease pathology have been made in autoimmune and neurodegenerative components. Despite the fact that brain is the most lipid rich organ in human body, the importance of lipid metabolism has not been extensively studied in this disorder. In MS, the CNS is under attack by a person's own immune system. Autoantigens and autoantibodies are known to cause devastation of myelin through up regulation of T-cells and cytokines, which penetrate through the blood-brain barrier to cause inflammation and myelin destruction. The anti-inflammatory role of high-density lipoproteins (HDLs) has been implicated in a plethora of biological processes: vasodilation, immunity to infection, oxidation, inflammation, and apoptosis. However, it is not known what role HDL plays in neurological function and myelin repair in MS. Understanding of lipid metabolism in the CNS and in the periphery might unveil new therapeutic targets and explain the partial success of some existing MS therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.